Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Accumulated Depreciation (2019 - 2022)

Historic Accumulated Depreciation for Avidity Biosciences (RNA) over the last 4 years, with Q3 2022 value amounting to $2.7 million.

  • Avidity Biosciences' Accumulated Depreciation rose 3854.32% to $2.7 million in Q3 2022 from the same period last year, while for Sep 2022 it was $2.7 million, marking a year-over-year increase of 3854.32%. This contributed to the annual value of $1.7 million for FY2021, which is 1243.05% down from last year.
  • As of Q3 2022, Avidity Biosciences' Accumulated Depreciation stood at $2.7 million, which was up 3854.32% from $2.4 million recorded in Q2 2022.
  • Avidity Biosciences' Accumulated Depreciation's 5-year high stood at $2.7 million during Q3 2022, with a 5-year trough of $1.6 million in Q4 2019.
  • Moreover, its 4-year median value for Accumulated Depreciation was $1.9 million (2020), whereas its average is $2.0 million.
  • As far as peak fluctuations go, Avidity Biosciences' Accumulated Depreciation plummeted by 1243.05% in 2021, and later skyrocketed by 3854.32% in 2022.
  • Quarter analysis of 4 years shows Avidity Biosciences' Accumulated Depreciation stood at $1.6 million in 2019, then rose by 20.45% to $2.0 million in 2020, then fell by 12.43% to $1.7 million in 2021, then skyrocketed by 58.05% to $2.7 million in 2022.
  • Its last three reported values are $2.7 million in Q3 2022, $2.4 million for Q2 2022, and $2.0 million during Q1 2022.